TG Therapeutics Gets Hold Consensus From Analysts
Nine analysts covering TG Therapeutics gave the stock a consensus Hold rating, with six buys, one hold, and two sells. The average one-year price target was $63.00, compared with a recent opening price of $57.43. Quarterly revenue rose 70.2% year over year to $240.34 million, though EPS of $0.05 missed the $0.31 consensus.
TG Therapeutics carries a mixed analyst view: six buy calls, one hold, and two sell calls, producing an overall Hold consensus. The average 12-month target sits at $63.00, while the article cites a recent opening price of $57.43. Recent quarterly revenue reached $240.34 million, a 70.2% year-over-year increase, but earnings per share came in at $0.05 against a $0.31 consensus estimate.
Ownership data show institutions hold 58.58% and insiders 8.87%. Director Laurence Charney sold 5,000 shares at an average of $54.96, leaving 168,640 shares. Analyst targets have varied widely, from $72 to $86 among several buy-rated firms, while one researcher downgraded the stock to strong sell.
The mixed analyst view and revenue growth alongside an EPS miss may shape investor sentiment, potentially affecting shareholders, employees, and patients who rely on the company’s therapies. A Hold consensus could reduce near-term volatility, while target-price gaps may influence trading. Broader market confidence in biopharma financing could be modestly affected, though single-company results rarely determine sector-wide outcomes.